Adoptive transfer of chimeric antigen receptor (CAR)-modified T lymphocytes has recently been proposed as advanced treatment for relapsed and refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia (ALL), CD19-positive lymphomas and multiple myeloma. Here, CD19 is linked to acute lymphoblastic leukemia.